Skip to Content

DaVita Inc DVA

Morningstar Rating
$137.41 −5.09 (3.57%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

DaVita's Outlook Remains Solid Despite Obesity Drug Threats

After selling DaVita Medical Group in 2019, DaVita focuses almost exclusively on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite some challenges emerging on the obesity drug front.

Price vs Fair Value

DVA is trading at a 474% premium.
Price
$137.41
Fair Value
$779.00
Uncertainty
High
1-Star Price
$813.90
5-Star Price
$65.80
Economic Moat
Grtzpff
Capital Allocation
Yvjmwfypj

Bulls Say, Bears Say

Bulls

After recent covid mortality challenges and obesity drug expansion, the ESRD patient population may grow at a healthy rate in the US and around the globe for the long run, which should benefit DaVita.

Bears

Potential US healthcare policy changes could reduce industry profitability if insurance coverage shifts away from employer-based plans and if Medicare reimbursement rates aren't changed significantly.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$142.50
Day Range
$136.30143.79
52-Week Range
$71.51147.93
Bid/Ask
$134.21 / $141.50
Market Cap
$12.05 Bil
Volume/Avg
830,983 / 890,250

Key Statistics

Price/Earnings (Normalized)
14.97
Price/Sales
1.03
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
5.39%

Company Profile

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
Sector
Healthcare
Industry
Medical Care Facilities
Stock Style Box
Mid Core
Total Number of Employees
70,000

Competitors

Valuation

Metric
DVA
THC
HCA
Price/Earnings (Normalized)
14.9717.2718.23
Price/Book Value
13.014.26
Price/Sales
1.030.741.40
Price/Cash Flow
6.408.299.23
Price/Earnings
DVA
THC
HCA

Financial Strength

Metric
DVA
THC
HCA
Quick Ratio
1.301.230.86
Current Ratio
1.431.441.16
Interest Coverage
4.365.815.07
Quick Ratio
DVA
THC
HCA

Profitability

Metric
DVA
THC
HCA
Return on Assets (Normalized)
6.99%3.29%9.68%
Return on Equity (Normalized)
118.17%50.21%
Return on Invested Capital (Normalized)
10.75%7.95%16.36%
Return on Assets
DVA
THC
HCA
See how this stock stacks up to its competitors with Morningstar Investor

Medical Care Facilities Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
HCA Healthcare Inc
HCA
LczzxqjvyMpfhhh$92.9 Bil
Fresenius SE & Co KGaA ADR
FSNUY
Qtqbrf$19.5 Bil
Fresenius SE & Co KGaA
FSNUF
Crktrw$19.5 Bil
Tenet Healthcare Corp
THC
FpnsprclpRdz$14.8 Bil
Universal Health Services Inc Class B
UHS
Gvqhvbb$14.3 Bil
Fresenius Medical Care AG
FMCQF
Ppdj$12.0 Bil
Fresenius Medical Care AG ADR
FMS
FqdRdlsm$12.0 Bil
Bangkok Dusit Medical Services PCL Shs Foreign Registered
BDULF
Lhshmyg$11.6 Bil
AMN Healthcare Services Inc
AMN
ZntwtfbyTlpmdbr$2.4 Bil

Sponsor Center